Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay

被引:89
作者
Altfeld, MA
Trocha, A
Eldridge, RL
Rosenberg, ES
Phillips, MN
Addo, MM
Sekaly, RP
Kalams, SA
Burchett, SA
McIntosh, K
Walker, BD
Goulder, PJR
机构
[1] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA
[5] Inst Rech Clin Montreal, Immunol Lab, Montreal, PQ H2W 1R7, Canada
关键词
D O I
10.1128/JVI.74.18.8541-8549.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte (CTL) responses play a major role in the antiviral immune response, but the relative contribution of CTL responses restricted by different HLA class I molecules is less well defined. HLA-B60 or the related allele B61 is expressed in 10 to 20% of Caucasoid populations and is even more highly prevalent in Asian populations, but yet no CTL epitopes restricted by these alleles have been defined. Here we report the definition of five novel HLA-B60-restricted HIV-1-specific CTL epitopes, using peripheral blood mononuclear cells in enzyme-linked immunospot (Elispot) assays and using CTL clones and lines in cytolytic assays. The dominant HLA-B60-restricted epitope, Nef peptide KEKG GLEGL, was targeted by all eight subjects with B60 and also by both subjects with B61 studied. This study additionally establishes the utility of the Elispot assay as a more rapid and efficient method of defining novel CTL epitopes. This approach will help to define new CTL epitopes that may play an important role in the immune control of HIV-1.
引用
收藏
页码:8541 / 8549
页数:9
相关论文
共 45 条
  • [1] HLA CLASS-I NUCLEOTIDE-SEQUENCES, 1995
    ARNETT, KL
    PERHAM, P
    [J]. TISSUE ANTIGENS, 1995, 46 (3-2): : 217 - 257
  • [2] HLA-B40, B18, B27, and B37 allele discrimination using group-specific amplification and SSCP method
    Bannai, M
    Tokunaga, K
    Lin, L
    Ogawa, A
    Fujisawa, K
    Juji, T
    [J]. HUMAN IMMUNOLOGY, 1996, 46 (02) : 107 - 113
  • [3] Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis
    Bertoni, R
    Sidney, J
    Fowler, P
    Chesnut, RW
    Chisari, FV
    Sette, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (03) : 503 - 513
  • [4] Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
    Borrow, P
    Lewicki, H
    Wei, XP
    Horwitz, MS
    Peffer, N
    Meyers, H
    Nelson, JA
    Gairin, JE
    Hahn, BH
    Oldstone, MBA
    Shaw, GM
    [J]. NATURE MEDICINE, 1997, 3 (02) : 205 - 211
  • [5] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    BORROW, P
    LEWICKI, H
    HAHN, BH
    SHAW, GM
    OLDSTONE, MBA
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (09) : 6103 - 6110
  • [6] T lymphocyte responses in HIV-1 infection: implications for vaccine development
    Brander, C
    Walker, B
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) : 451 - 459
  • [7] BRANDER C, 1999, HIV MOL DATABASE
  • [8] COMPREHENSIVE, SEROLOGICALLY EQUIVALENT DNA TYPING FOR HLA-B BY PCR USING SEQUENCE-SPECIFIC PRIMERS (PCR-SSP)
    BUNCE, M
    FANNING, GC
    WELSH, KI
    [J]. TISSUE ANTIGENS, 1995, 45 (02): : 81 - 90
  • [9] HLA and HIV-1:: Heterozygote advantage and B*35-Cw*04 disadvantage
    Carrington, M
    Nelson, GW
    Martin, MP
    Kissner, T
    Vlahov, D
    Goedert, JJ
    Kaslow, R
    Buchbinder, S
    Hoots, K
    O'Brien, SJ
    [J]. SCIENCE, 1999, 283 (5408) : 1748 - 1752
  • [10] Charron D., 1997, GENETIC DIVERSITY HL, P665